Literature DB >> 22059182

Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of Canadian pulmonary hypertension physicians.

Adrienne E Borrie1, David N Ostrow, Robert D Levy, John R Swiston.   

Abstract

BACKGROUND: Many treatment options are now available for patients with idiopathic pulmonary arterial hypertension (IPAH). Data regarding the optimal combination of therapies are lacking, as is consensus on how to assess response to therapy and when to change therapeutic regimens.
OBJECTIVES: To gather the opinions of Canadian pulmonary hypertension (PH) experts regarding standard practice in the care of IPAH patients after therapy is initiated.
METHODS: Canadian PH physicians were surveyed using short questionnaires to assess their opinions and practices in the care of IPAH patients. A Delphi forecasting approach was used to gain consensus among Canadian physicians on the most important clinical parameters to consider when assessing patients after the initiation of therapy.
RESULTS: Twenty-six of 37 Canadian PH experts who were invited to participate completed the study. All endorsed the use of combination therapy for IPAH patients despite the lack of universal provincial coverage for this approach. By consensus, WHO functional class, 6 min walk distance and hospitalization for right heart failure were the most important clinical parameters. The most highly rated physical examination parameters were jugular venous pressure, peripheral edema, the presence of ascites and body weight.
CONCLUSIONS: The overall approach to care of IPAH patients is similar across PH centres in Canada. A limited number of clinical and physical examination parameters were considered to be most important to reassess patients after therapy is initiated. These parameters, along with definition of threshold values, will facilitate the development of standard practice guidelines for IPAH patients in Canada.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22059182      PMCID: PMC3205105          DOI: 10.1155/2011/510874

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  18 in total

Review 1.  Treatment of pulmonary arterial hypertension.

Authors:  Marc Humbert; Olivier Sitbon; Gérald Simonneau
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

2.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

Review 3.  The current treatment of pulmonary arterial hypertension: time to redefine success.

Authors:  Stuart Rich
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

4.  Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland.

Authors: 
Journal:  Heart       Date:  2008-03       Impact factor: 5.994

Review 5.  Endothelin receptor antagonists in pulmonary arterial hypertension.

Authors:  J Dupuis; M M Hoeper
Journal:  Eur Respir J       Date:  2008-02       Impact factor: 16.671

6.  Survival with first-line bosentan in patients with primary pulmonary hypertension.

Authors:  V V McLaughlin; O Sitbon; D B Badesch; R J Barst; C Black; N Galiè; M Rainisio; G Simonneau; L J Rubin
Journal:  Eur Respir J       Date:  2005-02       Impact factor: 16.671

7.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.

Authors:  M M Hoeper; I Markevych; E Spiekerkoetter; T Welte; J Niedermeyer
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

Review 8.  The use of combination therapy in pulmonary arterial hypertension: new developments.

Authors:  N Galiè; L Negro; G Simonneau
Journal:  Eur Respir Rev       Date:  2009-09

9.  Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.

Authors:  M R Wilkins; J Wharton; F Grimminger; H A Ghofrani
Journal:  Eur Respir J       Date:  2008-07       Impact factor: 16.671

Review 10.  Prostacyclin therapies for the treatment of pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; H Olschewski
Journal:  Eur Respir J       Date:  2008-04       Impact factor: 16.671

View more
  4 in total

1.  The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.

Authors:  John J Ryan; Ghazwan Butrous; Bradley A Maron
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

2.  Treatment differences in pulmonary arterial hypertension management.

Authors:  Bradley A Maron; John J Ryan
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

3.  The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

Authors:  Haris M Vaid; Ximena Camacho; John T Granton; Muhammad M Mamdani; Zhan Yao; Samantha Singh; David N Juurlink; Tara Gomes
Journal:  Can Respir J       Date:  2016-04-11       Impact factor: 2.409

4.  Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature.

Authors:  Eduardo Vázquez-Garza; Judith Bernal-Ramírez; Carlos Jerjes-Sánchez; Omar Lozano; Edgar Acuña-Morín; Mariana Vanoye-Tamez; Martín R Ramos-González; Héctor Chapoy-Villanueva; Luis Pérez-Plata; Luis Sánchez-Trujillo; Guillermo Torre-Amione; Alicia Ramírez-Rivera; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2020-02-03       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.